• Investor Relations
• Myriad at a Glance
• Press Releases
• Events & Presentations
• Corporate Governance
• Management Team
• Board of Directors
• Financial Reporting
  • Latest Earnings Release
  • SEC Filings
  • Annual Reports
  • Quarterly Results
  • Key Ratios
• Stock Information
  • Historic Stock Lookup
  • Investment Calculator
  • Dividend History
  • Analyst Coverage
  • Request Information
• Frequently Asked Questions
• Contact

Investor Relations

Corporate Overview

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patient's lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence.

Why Invest in Myriad Genetics

Myriad's 9 molecular diagnostic tests provide a preeminent market position today; our 13 innovative pipeline tests will ensure Myriad's standing for the future. The Company is focused on three initiatives for long-term growth:

1. To grow existing tests and markets;
2. To expand internationally; and
3. To launch new products including companion diagnostics.

While Myriad is investing in its future, the company also boasts a balanced capital approach including returning cash to shareholders.

News Releases

Jun 17, 2013
DaVita Labs and Myriad RBM Announce Biomarker Research Collaboration

Jun 13, 2013
Supreme Court Upholds Myriad's cDNA Patent Claims

View all releases »

Events & Presentations

Myriad Corporate Presentation

View all events & presentations »